Excess in the pharmaceutical industry

被引：76

作者：

Angell, M ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Cambridge, MA 02138 USA

来源：

关键词：

D O I：

10.1503/cmaj.1041594

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1451 / 1453

页数：3

共 12 条

[1]

AARON C, 2003, OTHER DRUG WAR 2003

[2]

BOUTON D, 2003, PUBL FAMILIES US, V3106

[3]

Harris G, 2002, WALL STREET J A 0418, P1

[4]

HENSLEY S, 2003, WALL STREET J D 0415, P4

[5]

*HJ KAIS FAM FDN, 2001, PUBL HJ KAIS FAM FDN, V3112, P45

[6] Trends - Health spending rebound continues in 2002 [J].

Levit, K ;

Smith, C ;

Cowan, C ;

Sensenig, A ;

Catlin, A .

[7]

MAHAN D, 2002, PUBL FAMILIES US, V2105

[8]

PATTISON N, 2003, 2002 DRUG IND PROFIT

[9]

*PHRMA, 2002, PHARM IND PROF 2002, P79

Relman, AS .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (15) :2009-2012